Amoy Diagnostics
Xiamen, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A precision oncology diagnostics company developing PCR and NGS-based companion diagnostic kits for cancer, with a focus on accessibility and global partnerships.
Oncology
Technology Platform
Proprietary PCR (ADx-ARMS/Super-ARMS) and NGS (HANDLE/ddCapture) platforms with UMI integration for high-sensitivity detection of cancer-related gene mutations from tissue and liquid biopsy samples.
Opportunities
Growth opportunities include expanding its CDx portfolio through partnerships with global pharma for new targeted therapies, increasing penetration in international markets like Japan and Southeast Asia, and driving adoption of its newly launched comprehensive NGS panels.
Risk Factors
Key risks include intense competition from larger global diagnostic companies, regulatory and reimbursement challenges in new markets, and dependence on the adoption rates of the specific targeted therapies for which its tests are companions.
Competitive Landscape
Competes with global CDx leaders (e.g., Roche, Qiagen, Illumina's Grail) and Chinese peers (e.g., Burning Rock, Genetron). Differentiates through its proprietary, cost-effective PCR/NGS platforms, a strong track record of CDx approvals in Asia, and a focus on making complex testing 'easy to handle' in local labs.